Consolidated Statements Of Cash Flows (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net cash flows from operating activities:
Net income	$ 7,322	$ 16,172	$ 7,946
Adjustments to reconcile net income to net cash from operating activities:
Gain on sale of Medafor investment	(530)	(12,742)
Depreciation and amortization	6,028	5,843	5,633
Non-cash compensation	3,436	3,240	3,162
Other than temporary investment impairment		3,229	340
Write-down of inventories and deferred preservation costs	680	1,693	288
Deferred income taxes	178	617	1,227
Other non-cash adjustments to income	(474)	298	683
Changes in operating assets and liabilities:
Receivables	(4,556)	(1,637)	1,363
Inventories and deferred preservation costs	(1,131)	193	(1,598)
Prepaid expenses and other assets	(2,771)	(706)	(583)
Accounts payable, accrued expenses, and other liabilities	(64)	572	529
Net cash flows provided by operating activities	8,118	16,772	18,990
Net cash flows from investing activities:
Sales and maturities of restricted securities and investments	639
Proceeds from sale of Medafor investment	530	15,421
Capital expenditures	(4,310)	(4,338)	(3,070)
Purchases of restricted securities and investments	(1,208)	(20)
Acquisition of intangible assets	(1,010)	(196)	(819)
Acquisition of Hemosphere, net of cash acquired			(17,040)
Advances under notes receivable			(2,000)
Other	6	10	9
Net cash flows (used in) provided by investing activities	(5,353)	10,877	(22,920)
Net cash flows from financing activities:
Proceeds from exercise of stock options and issuance of common stock	2,675	2,207	330
Cash dividends paid	(3,295)	(2,967)	(1,373)
Repurchases of common stock	(5,588)	(1,523)	(3,310)
Redemption and repurchase of stock to cover tax withholdings	(1,483)	(681)	(219)
Other	738	(87)	(143)
Net cash flows used in financing activities	(6,953)	(3,051)	(4,715)
Effect of exchange rate changes on cash	(80)	36	(51)
(Decrease) increase in cash and cash equivalents	(4,268)	24,634	(8,696)
Cash and cash equivalents, beginning of year	37,643	13,009	21,705
Cash and cash equivalents, end of year	$ 33,375	$ 37,643	$ 13,009